יסינטק 130 מ"ג - Yesintek 130 mg
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L04AC Interleukin inhibitors |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V |
| צ×רת ××× ×× | תר××× ×××× ×ª ת×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | YESINTEK 130 MG is indicated for:Crohnâs Disease : YESINTEK 130 MG is indicated for the treatment of adult patients with moderately to severely active Crohnâs disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies. Ulcerative colitis : YESINTEK 130 MG is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 ××× ×¢××× ×ר××¤× Â |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ס×× ×ק 130 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BIOSIMILAR COLLABORATIONS IRELAND LIMITED, IRLAND |
| ×©× ××¢× ×ר×ש×× | DEXCEL LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 1/2025. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 12/12/2025 |
השינוי האחרון נעשה בֹ־12 בדצמבר 2025 ב־08:29